Sanofi Stock Price, News & Analysis (EPA:SAN)

€72.95 0.58 (0.80 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close€72.95
Today's Range€72.21 - €73.17
52-Week Range€71.06 - €92.97
Volume2.26 million shs
Average Volume2.24 million shs
Market Capitalization$92.15 billion
P/E Ratio20.21
Dividend Yield4.06%
BetaN/A

About Sanofi (EPA:SAN)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Receive SAN News and Ratings via Email

Sign-up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorHealthcare
SymbolEPA:SAN
CUSIPN/A
Phone+33-1-53774000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio20.207756232687
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS€3.61
Net IncomeN/A
Net Margins15.85%
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares1,260,000,000

Sanofi (EPA:SAN) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the EPA under the ticker symbol "SAN."

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2018?

14 analysts have issued twelve-month target prices for Sanofi's stock. Their predictions range from €75.00 to €100.00. On average, they expect Sanofi's share price to reach €87.86 in the next year. View Analyst Ratings for Sanofi.

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board (Age 66)
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director (Age 61)
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee (Age 59)
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel; Member of the Executive Committee (Age 58)
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets; Member of the Executive Committee (Age 54)
  • Roberto Pucci, Executive Vice President, Human Resources; Member of the Executive Committee (Age 53)
  • Peter Guenter, Executive Vice President, Diabetes & Cardiovascular; Member of the Executive Committee (Age 55)
  • David Loew, Executive Vice President, Sanofi Pasteur; Member of the Executive Committee
  • Philippe Luscan, Executive Vice President, Global Industrial Affairs; Member of the Executive Committee (Age 55)
  • Alan J. Main Ph.D., Executive Vice President, Consumer Healthcare; Member of the Executive Committee (Age 63)

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately €72.95.

How big of a company is Sanofi?

Sanofi has a market capitalization of $92.15 billion.

How can I contact Sanofi?

Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000.


MarketBeat Community Rating for Sanofi (SAN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  371 (Vote Outperform)
Underperform Votes:  460 (Vote Underperform)
Total Votes:  831
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sanofi (EPA:SAN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.292.292.272.27
Ratings Breakdown: 1 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €87.86€88.79€89.00€89.43

Sanofi (EPA:SAN) Consensus Price Target History

Price Target History for Sanofi (EPA:SAN)

Sanofi (EPA:SAN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/19/2018Deutsche BankSet Price TargetBuy€93.00View Rating Details
1/16/2018Jefferies GroupSet Price TargetNeutral€80.00View Rating Details
11/3/2017S&P GlobalSet Price TargetNeutral€83.00View Rating Details
11/3/2017Goldman Sachs GroupSet Price TargetNeutral€82.00View Rating Details
11/2/2017Berenberg BankSet Price TargetNeutral€97.00View Rating Details
11/2/2017JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
10/26/2017Morgan StanleySet Price TargetBuy€92.00View Rating Details
10/6/2017CitigroupSet Price TargetNeutral€88.00View Rating Details
9/12/2017BNP ParibasSet Price TargetNeutral€85.00View Rating Details
9/7/2017Kepler Capital MarketsSet Price TargetBuy€90.00View Rating Details
7/31/2017Sanford C. BernsteinSet Price TargetNeutral€90.00View Rating Details
7/4/2017Credit Suisse GroupSet Price TargetBuy€95.00View Rating Details
5/8/2017BarclaysSet Price TargetSell€75.00View Rating Details
3/23/2017Societe GeneraleSet Price TargetBuy€100.00View Rating Details
12/6/2016S&P GlobalSet Price TargetNeutral€80.00View Rating Details
6/30/2016Independent ResearchSet Price TargetNeutral€77.00View Rating Details
6/9/2016Baader BankSet Price TargetNeutral€78.00View Rating Details
2/9/2016S&P Equity ResearchSet Price TargetBuy€85.00View Rating Details
(Data available from 1/20/2016 forward)

Earnings

Earnings History for Sanofi (EPA:SAN)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Sanofi (EPA:SAN) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sanofi (EPA:SAN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sanofi (EPA SAN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Sanofi (EPA SAN) News Headlines

Source:
DateHeadline
Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive CommitteeSanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee
finance.yahoo.com - January 19 at 3:16 PM
Big Pharma, Big DividendsBig Pharma, Big Dividends
www.forbes.com - January 18 at 3:17 PM
Alnylam stock more than tripled last year — and the company says 2018 will be bigAlnylam stock more than tripled last year — and the company says 2018 will be big
finance.yahoo.com - January 17 at 3:16 PM
Sanofi (SAN) PT Set at €80.00 by Jefferies GroupSanofi (SAN) PT Set at €80.00 by Jefferies Group
www.americanbankingnews.com - January 16 at 9:34 AM
Flu season ramped up in last weeks of 2017Flu season ramped up in last weeks of 2017
finance.yahoo.com - January 12 at 5:25 AM
Regeneron, Sanofi Expand Investment in Cemiplimab & DupilumabRegeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab
finance.yahoo.com - January 9 at 3:15 PM
Alnylam, Sanofi to restructure rare-disease effort - MarketWatchAlnylam, Sanofi to restructure rare-disease effort - MarketWatch
www.marketwatch.com - January 9 at 5:36 AM
Biotech CEO Turned Failed Sanofi Drug Into Multibillion Deal - BloombergBiotech CEO Turned Failed Sanofi Drug Into Multibillion Deal - Bloomberg
www.bloomberg.com - January 9 at 5:36 AM
Biotech CEO Turned Failed Sanofi Drug Into Multibillion DealBiotech CEO Turned Failed Sanofi Drug Into Multibillion Deal
finance.yahoo.com - January 9 at 5:36 AM
Sanofi : Disclosure of trading in own sharesSanofi : Disclosure of trading in own shares
finance.yahoo.com - January 8 at 3:16 PM
APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with Sanofi - GlobeNewswire (press release)APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with Sanofi - GlobeNewswire (press release)
globenewswire.com - January 8 at 11:19 AM
Sanofi to market new hemophilia drug in deal with Alnylam - ReutersSanofi to market new hemophilia drug in deal with Alnylam - Reuters
www.reuters.com - January 8 at 11:19 AM
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs - GlobeNewswire (press release)Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs - GlobeNewswire (press release)
globenewswire.com - January 8 at 11:19 AM
Targovax announces the appointment of Michael Bogenstaetter as Chief Business OfficerTargovax announces the appointment of Michael Bogenstaetter as Chief Business Officer
feeds.benzinga.com - January 8 at 2:59 AM
Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance - Business Wire (press release)Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance - Business Wire (press release)
www.businesswire.com - January 7 at 3:15 PM
Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease allianceSanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
finance.yahoo.com - January 7 at 3:15 PM
Brainstorm Health: RNA Interference, Sanofi Dengue Vaccine ... - FortuneBrainstorm Health: RNA Interference, Sanofi Dengue Vaccine ... - Fortune
fortune.com - January 5 at 5:25 AM
Brainstorm Health: RNA Interference, Sanofi Dengue Vaccine, Quartet Funding, Philip MorrisBrainstorm Health: RNA Interference, Sanofi Dengue Vaccine, Quartet Funding, Philip Morris
www.msn.com - January 4 at 3:16 PM
Sanofi says will work with Manila in spite of Dengvaxia banSanofi says will work with Manila in spite of Dengvaxia ban
finance.yahoo.com - January 4 at 3:16 PM
Philippines fines Sanofi, suspends clearance for DengvaxiaPhilippines fines Sanofi, suspends clearance for Dengvaxia
finance.yahoo.com - January 4 at 5:20 AM
Sanofi (SAN) Receives Average Recommendation of "Hold" from AnalystsSanofi (SAN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 1 at 8:02 AM
3 Top Value Stocks to Buy in 20183 Top Value Stocks to Buy in 2018
finance.yahoo.com - December 31 at 3:16 PM
Healthcare Net Gains Leaders For 2018 Are Glaxo, Sanofi, Merck, Owens, Novartis, And Pfizer Per Broker TargetsHealthcare Net Gains Leaders For 2018 Are Glaxo, Sanofi, Merck, Owens, Novartis, And Pfizer Per Broker Targets
www.msn.com - December 30 at 3:17 PM
Healthcare Net Gains Leaders For 2018 Are Glaxo, Sanofi, Merck, Owens, Novartis, And Pfizer Per Broker Targets - Seeking AlphaHealthcare Net Gains Leaders For 2018 Are Glaxo, Sanofi, Merck, Owens, Novartis, And Pfizer Per Broker Targets - Seeking Alpha
seekingalpha.com - December 29 at 8:48 AM
Understanding Sanofi’s 3Q17 Performance by Business SegmentUnderstanding Sanofi’s 3Q17 Performance by Business Segment
finance.yahoo.com - December 26 at 6:23 PM
What’s AstraZeneca’s Valuation in December 2017?What’s AstraZeneca’s Valuation in December 2017?
finance.yahoo.com - December 21 at 5:32 AM
Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate - Nasdaq ... - NasdaqAlnylam/Sanofi Submit MAA in Europe for RNAi Candidate - Nasdaq ... - Nasdaq
www.nasdaq.com - December 20 at 5:23 AM
BofA/Merrill Lynch Remains Sidelined on Sanofi (SNY) Following ... - StreetInsider.comBofA/Merrill Lynch Remains Sidelined on Sanofi (SNY) Following ... - StreetInsider.com
www.streetinsider.com - December 19 at 5:31 AM
Alnylam and Sanofi Submit Marketing Authorisation Application ... - Business Wire (press release)Alnylam and Sanofi Submit Marketing Authorisation Application ... - Business Wire (press release)
www.businesswire.com - December 19 at 5:31 AM
Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the ... - GlobeNewswire (press release)Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the ... - GlobeNewswire (press release)
www.globenewswire.com - December 19 at 5:31 AM
BRIEF-Sanofi And Alnylam Submit Marketing Authorization To EMA For PatisiranBRIEF-Sanofi And Alnylam Submit Marketing Authorization To EMA For Patisiran
www.reuters.com - December 18 at 3:15 PM
Sanofi and Alnylam submit Marketing Authorization Application  to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosisSanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
feeds.benzinga.com - December 18 at 7:28 AM
[$$] Philippines Probes Dengue Vaccination Drive That Went Ahead Despite Warnings[$$] Philippines Probes Dengue Vaccination Drive That Went Ahead Despite Warnings
finance.yahoo.com - December 18 at 5:29 AM
[$$] Manila Investigates Dengue Vaccination Drive[$$] Manila Investigates Dengue Vaccination Drive
finance.yahoo.com - December 18 at 5:29 AM
Mylan Announces IPR Proceedings for Sanofis Lantus Patents ... - NasdaqMylan Announces IPR Proceedings for Sanofi's Lantus Patents ... - Nasdaq
www.nasdaq.com - December 16 at 5:36 AM
Sanofi: FDA lifts clinical hold on fitusiran - GlobeNewswire (press release)Sanofi: FDA lifts clinical hold on fitusiran - GlobeNewswire (press release)
globenewswire.com - December 15 at 3:16 PM
Alnylam Gets Some Welcome NewsAlnylam Gets Some Welcome News
finance.yahoo.com - December 15 at 3:16 PM
Sanofi: FDA lifts clinical hold on fitusiranSanofi: FDA lifts clinical hold on fitusiran
feeds.benzinga.com - December 15 at 7:55 AM
Sanofi Wants to Go It Alone -- Good Luck With That - BloombergSanofi Wants to Go It Alone -- Good Luck With That - Bloomberg
www.bloomberg.com - December 14 at 3:16 PM
Sanofi Wants to Go It Alone -- Good Luck With ThatSanofi Wants to Go It Alone -- Good Luck With That
finance.yahoo.com - December 14 at 3:16 PM
Sanofis planned marketing application for diabetes med propels licensor Lexicon Pharmaceuticals, up 4% - Seeking AlphaSanofi's planned marketing application for diabetes med propels licensor Lexicon Pharmaceuticals, up 4% - Seeking Alpha
seekingalpha.com - December 14 at 5:33 AM
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
finance.yahoo.com - December 14 at 5:33 AM
Sanofi expects to file nine regulatory submissions over next 18 months - Seeking AlphaSanofi expects to file nine regulatory submissions over next 18 months - Seeking Alpha
seekingalpha.com - December 13 at 3:17 PM
Sanofi looks to pipeline after setbacks - Financial TimesSanofi looks to pipeline after setbacks - Financial Times
www.ft.com - December 13 at 3:17 PM
Top 10 Generic Pharmaceutical Companies In 2017Top 10 Generic Pharmaceutical Companies In 2017
finance.yahoo.com - December 13 at 3:17 PM
Did Sanofi, WHO ignore warning signals on dengue vaccine? - ReutersDid Sanofi, WHO ignore warning signals on dengue vaccine? - Reuters
www.reuters.com - December 13 at 5:32 AM
Sanofi : Sanofi presents R&D strategy and innovative pipeline - GlobeNewswire (press release)Sanofi : Sanofi presents R&D strategy and innovative pipeline - GlobeNewswire (press release)
globenewswire.com - December 13 at 5:32 AM
Sanofi sees nine regulatory submissions over next 18 monthsSanofi sees nine regulatory submissions over next 18 months
finance.yahoo.com - December 13 at 5:32 AM
Sanofi : Sanofi presents R&D strategy and innovative pipelineSanofi : Sanofi presents R&D strategy and innovative pipeline
finance.yahoo.com - December 13 at 5:32 AM
Frances Sanofi pins hopes on new drugs after setbacksFrance's Sanofi pins hopes on new drugs after setbacks
finance.yahoo.com - December 13 at 5:32 AM

SEC Filings

Sanofi (EPA:SAN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Sanofi (EPA SAN) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.